Samsung Biologics Outlines Key Business Achievements and 2025 Outlook at the J.P. Morgan Healthcare Conference
Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), recently presented its latest business developments and 2025 outlook at the 43rd annual J.P. Morgan Healthcare Conference held in San Francisco from January 13-16. The company shared updates on its significant achievements and plans for expansion, aimed at positioning itself as a key player in the biopharmaceutical manufacturing sector.
In his keynote presentation, Samsung Biologics’ CEO and President, John Rim, emphasized the company’s readiness for a new phase of growth, despite the challenges faced by the industry. “Despite the industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and the launch of antibody-drug conjugate (ADC) services,” Rim said. He also highlighted the company’s commitment to continued investment in new technologies and modalities to meet client needs and maintain its high standards of product quality. “We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products,” he added.
Expanding ADC Services to Meet Growing Demand
A key highlight of Samsung Biologics’ business update was the introduction of its dedicated antibody-drug conjugate (ADC) services. With the increasing demand for ADC-based therapeutics, Samsung Biologics has launched ADC services at its new, state-of-the-art facility. This new facility strengthens the company’s position as a leader in large-scale antibody manufacturing and process engineering.
Samsung Biologics’ ADC service offering spans the entire lifecycle of ADC development, from late-stage discovery and development to the conjugation process. The company’s technical expertise in manufacturing monoclonal antibodies allows it to support complex and challenging ADC programs. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support several of their ADC programs. This partnership marks an important step forward in leveraging its new facility to meet the growing demand for ADC-based treatments.
Opening of a Regional Office in Japan
In line with its global expansion strategy, Samsung Biologics announced plans to open a regional office in Tokyo, Japan, in 2025. The new office will enable the company to better support its growing client base in the region and facilitate deeper collaborations with Japanese pharmaceutical and biotechnology companies. As the demand for biopharmaceutical manufacturing services continues to rise across Asia, this local presence in Japan is expected to further strengthen Samsung Biologics’ relationships with its partners and enhance its ability to deliver tailored services to its clients.
The move into Japan reflects Samsung Biologics’ ongoing commitment to building a global infrastructure that allows it to meet the needs of clients across multiple regions. By establishing a closer presence in Japan, Samsung Biologics aims to capitalize on the country’s burgeoning biopharmaceutical sector and strengthen its market position in Asia.
Expansion of Drug Product (DP) Services
Samsung Biologics is also expanding its Drug Product (DP) services as part of its broader efforts to offer a comprehensive range of capabilities to clients in the biopharmaceutical sector. The company is investing in the development of pre-filled syringe (PFS) capabilities, an important advancement in the manufacturing of injectable biologics. This fully automated PFS DP line is expected to be cGMP (current Good Manufacturing Practice) ready by 2027, enabling Samsung Biologics to meet the rising demand for high-quality injectable drug products.
The expansion of DP services is part of the company’s broader strategy to diversify its offerings and enhance its value proposition to clients. With the increasing focus on patient-friendly delivery formats such as pre-filled syringes, Samsung Biologics is positioning itself to meet the evolving needs of the pharmaceutical industry and ensure the efficient and safe delivery of biologic drugs.
Enhancing Development Capabilities with Advanced Technologies
To better support global pharmaceutical and emerging biotech companies, Samsung Biologics is also making significant investments in its development capabilities. The company has introduced a suite of advanced technologies that will play a key role in accelerating the drug development process while ensuring the highest levels of quality and productivity.
Samsung Biologics is offering a range of innovative tech platforms, including S-HiCon™, S-Tensify™, S-AfuCHO™, and S-OptiCharge™, which are designed to enhance the productivity and performance of biologic molecules. These platforms focus on streamlining various aspects of the drug development process, from cell line development and protein production to formulation and analytical testing. By integrating these technologies into its services, Samsung Biologics is aiming to accelerate drug development timelines and increase the likelihood of successful outcomes for its clients.
The incorporation of these advanced technologies ensures that Samsung Biologics can meet the needs of its clients, particularly in the area of biologics and biosimilars. The company’s continued investment in cutting-edge development capabilities positions it as a trusted partner for pharmaceutical companies looking to bring new and innovative drugs to market faster and more efficiently.
Bio Campus II Expansion and Capacity Growth
Samsung Biologics is also embarking on a major capacity expansion project with the opening of Bio Campus II in 2025. This new facility will mark a new phase of growth for the company, significantly increasing its manufacturing capacity to meet the surging demand for biologic products. Plant 5, the first facility of Bio Campus II, is scheduled to be operational by April 2025, bringing Samsung Biologics’ total manufacturing capacity to 784,000 liters.
The company is also considering the construction of a sixth plant to further expand its manufacturing capacity. If approved, this facility would increase total production capacity to 964,000 liters, reinforcing Samsung Biologics’ ability to support the growing demand for biologics on a global scale. The expansion of Bio Campus II is a critical step in ensuring that Samsung Biologics can continue to meet the needs of its clients and maintain its leadership in the biologics manufacturing sector.
Investing in Digital Transformation
In addition to its investments in physical infrastructure and technological capabilities, Samsung Biologics is also embracing digital transformation as a key driver of operational efficiency and client satisfaction. The company is building integrated digital systems that span quality control, manufacturing, and operations, all aimed at providing clients with enhanced insight and data-driven solutions.
By incorporating artificial intelligence (AI) and digital twin technology into its operations, Samsung Biologics aims to optimize manufacturing processes, improve quality control, and streamline project timelines. Digital twin technology, in particular, enables the creation of virtual models of physical processes, allowing for real-time monitoring and optimization. This will allow Samsung Biologics to provide clients with actionable insights and optimize project timelines without compromising on quality.
The company’s commitment to digital transformation is part of a broader effort to enhance client satisfaction by providing more efficient, transparent, and data-enabled services. As the biopharmaceutical industry continues to evolve, Samsung Biologics aims to stay ahead of the curve by leveraging digital technologies to offer more sophisticated solutions and better meet the needs of its clients.
Samsung Biologics’ presentation at the 2025 J.P. Morgan Healthcare Conference showcased the company’s continued growth and commitment to innovation. With plans to expand its capabilities in ADC services, drug product manufacturing, and development technologies, Samsung Biologics is positioning itself as a leader in the global biopharmaceutical manufacturing space. The opening of Bio Campus II and the planned expansion of its manufacturing capacity underscore the company’s readiness to meet the increasing demand for biologics and support the rapid growth of the pharmaceutical industry.
By continuing to invest in advanced technologies, digital transformation, and global expansion, Samsung Biologics is well-equipped to navigate the challenges of the industry and drive future growth. The company’s focus on delivering high-quality products, improving operational efficiency, and enhancing client satisfaction ensures that it will remain a trusted partner for pharmaceutical and biotechnology companies around the world. As Samsung Biologics enters 2025, it is poised to play a pivotal role in shaping the future of biologic drug manufacturing.
